VS-4718
- Generic Name
- VS-4718
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H26F3N5O3
- CAS Number
- 1061353-68-1
- Unique Ingredient Identifier
- L2BD0MW4OL
- Background
VS-4718 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).
- Associated Conditions
- -
- Associated Therapies
- -
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Verastem, Inc.
- Registration Number
- NCT02215629
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01849744
- Locations
- 🇺🇸
Washington University School of Medicine, Division of Oncology, Saint Louis, Missouri, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath